FOR PATIENTS
FOR CLINICIANS
FOR THE PRESS
THE EXPERTS GROUP
MEDIA POOL
> SIRT > Data protection
 

DATA PROTECTION POLICY

Data protection

We gather and use personal data exclusively within the context of the provisions of the Federal Data Protection Act (BDSG) and the Telemedia Act (TMG). Your data is used solely by us. It is not passed on to third parties. Our employees are obliged to maintain confidentiality.

 

Data transmission and data logging

When you visit our websites, your internet browser automatically transmits data to our webserver. The current IP address being used, the date and time of the visit and the browser type and version are recorded. It is not possible to attribute this data to specific individuals. The data is deleted following statistical analysis.

 

Usage data

We gather and use personal data from you if this is needed to allow you to use our internet-based services. Upon instruction from the relevant bodies, we are obliged, in individual cases, to disclose this data if it is required for the purposes of law enforcement, hazard prevention, the fulfilment of legal obligations of the intelligence services or military defence service, or to assert intellectual property rights.

 

Cookies

To optimise our internet services, we use cookies. Cookies are small text files that your internet browser creates and stores on your computer. Cookies allow your use of the internet to be more effective. Cookies themselves only identify anonymously the computer’s IP address and do not save any personal information such as the user’s name. Since such information cannot be readily used to identify a natural person individually, the use of cookies is permitted. You have the choice of whether to allow cookies or not. You can prevent cookies from being stored by making appropriate settings in your browser.

 

Contact option

On our website, we offer you the opportunity to contact us by e-mail. In this case, the information provided by the user will be saved in order to allow the contact request to be processed. It is not passed on to third parties. There is also no comparison of the data gathered in such a manner with data that may be collected by other elements of our website.

 

Right to information and revocation / deletion

You have the right to find out about the information we hold about you. You can ask us to block, correct or delete the data we have gathered on you at any time.

 

Data collection by Google Analytics

This website uses Google Analytics, a web analysis service from Google Inc. (“Google”). Google Analytics uses “cookies”, text files that are stored on your computer and which permit an analysis of your use of the website. The information generated by the cookie regarding your use of this website is generally transferred to a server owned by Google in the USA and stored there. If IP anonymisation is enabled on this website, Google first truncates your IP address within the Member States of the European Union or in other states of the European Economic Area Agreement. The full IP address is only communicated in full to a Google server in the USA in exceptional cases and truncated there. Google will use this information on behalf of the operator of this website to evaluate your use of the website in order to put together reports on website activities and in order to provide other services related to website use and Internet use. The IP address communicated by your browser as part of the Google Analytics is not merged with other data by Google. You can prevent the installation of cookies by making the appropriate settings in your browser software; we do point out, however, that by doing so you may be unable to use the full functionality of this website. You can also prevent any data generated by the cookie or data relating to your use of this website (including your IP address) from being transferred to Google or being processed by Google by downloading and installing the browser plug-in available via the following link: (http://tools.google.com/dlpage/gaoptout?hl=de).
You can prevent data being collected by Google Analytics by clicking on the following link. An opt-out cookie is stored which prevents the future collection of your data when you visit this website:
» Deactivate Google Analytics

 

More information about the terms of use and data protection can be found at http://www.google.com/analytics/terms/de.html or https://www.google.de/intl/de/policies/. We would like to point out that Google Analytics has been suffixed with the code “gat._anonymizeIp();” on this website in order to ensure the anonymised capture of IP addresses (known as IP masking).
We also use Google Analytics to evaluate data from AdWords and the double-click cookie for statistical purposes. If you do not wish us to do this, you can disable this via the advertising specifications manager (http://www.google.com/settings/ads/onweb/?hl=de).

 

Source: www.datenschutzbeauftragter-info.de

 
NEWS & DATES
More treatment options are necessary for patients with metastatic colorectal cancer – Colorectal cancer prevention is getting more and more attention. However, every third colorectal cancer patient develops metastases in the course of the disease – often in the liver. For these patients, more and better therapy options are needed. Local therapies offer promising opportunities.To the press release
The new ESMO guidelines recommend SIRT for people with metastatic colorectal cancer if the metastases are limited to the liver and are not responding to chemotherapy.
New evidence of the benefits of SIRT in mCRC – The depth-of-response data from the SIRFLOX study shows a significantly larger local depth of response through the combination of SIRT and chemotherapy. To the press release
Metastatic colorectal cancer: the SIRFLOX, FOXFIRE and FOXFIRE Global studies are investigating the benefits of combining SIRT with chemotherapy. The data from the three studies regarding overall survival is expected by the end of 2017. The SARAH and SIRveNIB studies on advanced liver cell cancer are now complete. Both compared Y90 radio-embolisation with sorafenib chemotherapy. The initial results are set to be published at the end of 2016 (SARAH) and 2017 (SIRveNIB).
The SIRT Experts Group is a partner of: